Industry News

• Abbott Fund Institute of Nutrition Science at Bach Mai Hospital established  The Abbott Fund and the Global Health Primary Care Initiative (GHPCI) at the Boston University School of Medicine joined Bach Mai Hospital, the National Institute of Nutrition (NIN) and Hanoi Medical University to announce the opening of the Abbott Fund Institute of Nutrition Science (AFINS).
  Abbott March 19, 2010  
• Scientific data relating to Cinryze(TM) (C1 esterase inhibitor [human]) presented  ViroPharma announced the presentation of two abstracts relating to Cinryze(TM) (C1 esterase inhibitor [human]) therapy at the First International Congress of the Southern European Allergy Society in Florence, Italy.
  ViroPharma Incorporated March 19, 2010  
• ViroPharma launches 'Ryze Above(TM)', A personalized patient resources program for HAE  ViroPharma announced the launch of 'Ryze Above', an exclusive patient resources program within the company's patient support program, CINRYZESolutions(R).
  ViroPharma Incorporated March 19, 2010  
• OSI Pharmaceuticals announces that Tarceva(R) received a positive opinion from EU  OSI Pharmaceuticals announced that its international partner for Tarceva(R) (erlotinib), Roche, informed OSI that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Tarceva as monotherapy for maintenance treatment for NSCLC.
  OSI Pharmaceuticals, Inc. March 19, 2010  
• Mayo research: intervention drops hospital infection rate by a third  Clostridium difficile is the one of the leading pathogens causing hospital-acquired infection in the U.S. It may cause diarrhea, colitis, sepsis and lead to prolonged hospitalization and death. Mayo Clinic researchers say they've found a way to reduce the acquisition of this infection.
  Mayo Clinic March 19, 2010  
• NIH announces genetic testing registry  The National Institutes of Health announced that it is creating a public database that researchers, consumers, health care providers, and others can search for information submitted voluntarily by genetic test providers.
  National Institutes of Health March 18, 2010  
• Jury rules in favour of AstraZeneca in first US Seroquel product liability trial  AstraZeneca announced that a jury in a New Jersey state court in the US ruled in favour of AstraZeneca by rejecting a Louisiana plaintiff's claims that SEROQUEL caused his alleged injuries. The case, Baker v. AstraZeneca, was the first product liability case to go to trial.
  AstraZeneca March 18, 2010  
• ZIOPHARM reports fourth quarter and full year 2009 financial results  The Company reported net income of $1.0 million, or $0.03 per share for the quarter ended December 31, 2009, compared to a net loss of 4.6 million, or $(0.21) per share, in the fourth quarter of 2008.
  ZIOPHARM Oncology, Inc. March 18, 2010  
• FDA approves Envoy Medical 's first totally implanted hearing system   The FDA announced the approval of the Esteem – an implanted hearing system used to treat moderate to severe sensorineural hearing loss, a type of permanent hearing loss. As a condition of FDA approval, Esteem manufacturer, Envoy Medical of St. Paul, Minn., must conduct two post-approval studies.
  U.S. Food and Drug Administration March 18, 2010  
• ALS Therapy Institute pairs with N.J. biotech  Cambridge-based ALS Therapy Institute has teamed up with a New Jersey biotech to test several small-molecule compounds that have the potential to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS), commonly called Lou Gehrig's disease.
  Mass High Tech March 17, 2010  

   (next 10 articles)